Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AQXP

Aquinox Pharmaceuticals (AQXP) Stock Price, News & Analysis

Aquinox Pharmaceuticals logo

About Aquinox Pharmaceuticals Stock (NASDAQ:AQXP)

Key Stats

Today's Range
$20.96
$22.07
50-Day Range
$3.68
$4.03
52-Week Range
$2.00
$3.84
Volume
89,409 shs
Average Volume
239,362 shs
Market Capitalization
$508.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive AQXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquinox Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AQXP Stock News Headlines

Mirum Pharmaceuticals, Inc. (MIRM)
Why Aquinox Pharma (AQXP) Stock Might be a Great Pick
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
See More Headlines

AQXP Stock Analysis - Frequently Asked Questions

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) posted its earnings results on Thursday, November, 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.43.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aquinox Pharmaceuticals investors own include Novavax (NVAX), Bausch Health Cos (BHC), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), XOMA Royalty (XOMA), Alnylam Pharmaceuticals (ALNY) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/08/2018
Today
8/13/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AQXP
CIK
1404644
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$31.58 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-30.13%
Return on Assets
-28.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
63.17
Quick Ratio
63.17

Sales & Book Value

Annual Sales
$25 million
Price / Sales
20.35
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.09 per share
Price / Book
6.99

Miscellaneous

Outstanding Shares
23,540,000
Free Float
N/A
Market Cap
$508.70 million
Optionable
Not Optionable
Beta
-7.37
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:AQXP) was last updated on 8/13/2026 by MarketBeat.com Staff.
From Our Partners